Loading the records…
Loading the records…
The Expedited Access to Biosimilars Act would reduce clinical study requirements for biosimilar approval, lowering development costs and time to market for biosimilar manufacturers. This is bullish for companies like Viatris ($VTRS), Amgen ($AMGN), and Pfizer ($PFE) that have significant biosimilar pipelines.
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
The bill is structurally bullish for biosimilar developers. $VTRS, with its deep biosimilar pipeline and higher sensitivity to regulatory changes, is the most leveraged play. $AMGN and $PFE have broader portfolios but still benefit. The stock reactions will depend on passage probability; near-term, the committee advancement is a positive signal but not a catalyst until floor votes. No real market price data is provided, so no fabricated moves.
On July 22, 2026, the Senate Committee on Health, Education, Labor, and Pensions ordered the Expedited Access to Biosimilars Act (S.1414) to be reported favorably with an amendment. The bill, sponsored by Sen. Rand Paul (R-KY) and cosponsored by Sens. Mike Lee (R-UT) and Maggie Hassan (D-NH), now awaits floor action in the Senate. The legislation amends the Public Health Service Act to eliminate the requirement that clinical studies for biosimilar licensure include assessments of immunogenicity, pharmacodynamics, or comparative clinical efficacy. Instead, the FDA may require such studies at its discretion only with a written justification notice.
There is no direct funding in this bill—it is a regulatory relief measure. By reducing mandatory clinical trial requirements, the bill lowers the cost and time to bring biosimilars to market. This directly benefits biosimilar developers by accelerating approval timelines and reducing development costs, which can total hundreds of millions per product. Originator biologic makers may face increased competition, but the net impact on diversified pharma companies depends on their biosimilar exposure.
The bill has bipartisan support and advanced from committee swiftly (from introduction in April 2025 to committee markup in July 2026). Next steps: Senate floor vote, then House passage. Given the bipartisan co-sponsorship and relatively narrow scope, passage is plausible in the current Congress.
Structural winners are pure-play biosimilar and generic companies with large biosimilar pipelines. Viatris ($VTRS) derives ~20% of revenue from biosimilars and generics; lower regulatory burden could expand margins and speed launches. Amgen ($AMGN) has both originator and biosimilar businesses, but its biosimilar segment is growing and stands to benefit. Pfizer ($PFE) has a smaller biosimilar portfolio but could see incremental cost savings. The measured approach—FDA retains discretion—reduces risk of lower safety standards, which may ease opposition.
Matched on shared policy language across AI analyses, with ticker & timing weight
To amend the Public Health Service Act to codify that the default expectation for licensure of biological products as biosimilar does not include clinical studies assessing pharmacodynamics or comparative clinical efficacy, and for other purposes.
Affordable Prescriptions for Patients Act
A bill to amend the Public Health Service Act to streamline the review of biosimilar biological products.
Biosimilars Access and Affordability Act
Executive orders & memoranda affecting the same sectors or companies
This executive order establishes a Women's Health Division within the NIH to coordinate and accelerate research on understudied women's health conditions, and creates a White House Women's Health Task Force to drive policy reforms and translation of research into clinical practice across federal agencies. It directs specific agencies to prioritize research, data collection, and translation into prevention, diagnosis, and treatment, with a focus on all life stages from infancy through aging.
This executive order directs the Secretaries of State, Labor, and Homeland Security to coordinate with Commerce, Education, and the SBA when processing H-1B petitions, and requires them to consider whether the employer has engaged in layoffs of similarly situated U.S. workers within the past year. It also orders the Labor Department to review past labor condition applications for potential enforcement actions against sponsoring employers, effectively tightening scrutiny on H-1B usage, especially by outsourcing firms.
This proclamation orders the Secretaries of War and Veterans Affairs to mandate rapid, ongoing digital sharing of military personnel and medical records, deploy AI-powered tools for benefits applications, and update existing IT contracts for interoperability. It also requires the Transition Assistance Program to connect separating service members to specific jobs or training programs before discharge.
Free — no credit card
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →